The use of immunotherapeutic agents, nucleoside antimetabolites, and platinum-based drugs in the preparation of anti-tumor drugs.

The combination therapy of PD-1 antibody with gemcitabine and cisplatin has solved the problems of local recurrence and distant metastasis of nasopharyngeal carcinoma, achieving a highly effective and safe treatment effect, especially in recurrent or metastatic nasopharyngeal carcinoma, showing significant relief and control effects.

CN111093703BActive Publication Date: 2026-11-17JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201880059097.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-11-17
Filing Date
2018-11-16
Publication Date
2026-11-17
Estimated Expiration
2038-11-16

AI Technical Summary

Technical Problem

In the current treatment of nasopharyngeal carcinoma, local recurrence and distant metastasis remain the main causes. The application of PD-1 monoclonal antibody combined with chemotherapy in nasopharyngeal carcinoma is rare and there are problems with drug resistance. A combination therapy is needed to improve efficacy and reduce toxicity.

Method used

Combining PD-1 antibodies with nucleoside antimetabolites gemcitabine and platinum complex cisplatin, optimizing dosage and administration regimens, and enhancing T-cell activity for the treatment of nasopharyngeal carcinoma, including the light and heavy chain variable region sequences of humanized antibodies, combined with different chemotherapy cycles and dosing frequencies.

Benefits of technology

It demonstrated good safety and high efficacy, with a remission rate of 90.9% and a control rate of 100%, and reduced toxic adverse reactions. It is suitable for recurrent or metastatic nasopharyngeal carcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GPA0000285931470000041
    Figure GPA0000285931470000041
  • Figure GPA0000285931470000042
    Figure GPA0000285931470000042
  • Figure GPA0000285931470000051
    Figure GPA0000285931470000051
Patent Text Reader

Abstract

This invention provides the use of immunotherapeutic agents, nucleoside antimetabolites, and platinum-based compounds in the preparation of medicaments for treating tumors. Specifically, this invention provides the use of PD-1 antibodies, gemcitabine, and cisplatin in the preparation of medicaments for treating nasopharyngeal carcinoma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention provides the use of a combination of immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes in the preparation of a medicament for treating nasopharyngeal carcinoma. Background Technology

[0002] Nasopharyngeal carcinoma (NPC) is a common malignant tumor in southern my country and Southeast Asia. It is highly malignant and metastasizes early; approximately 30%-50% of NPC patients have already developed cervical lymph node metastasis and distant metastasis at the time of diagnosis. With the gradual improvement of diagnostic and treatment methods for NPC, the local control rate of NPC patients has significantly improved. However, local recurrence and distant metastasis remain the main causes of treatment failure. Radiotherapy or concurrent chemoradiotherapy remains the primary treatment for early or locally advanced NPC, with a 5-year survival rate of around 85%. However, these patients will eventually experience recurrence or metastasis, and 15% of NPC patients are diagnosed with distant metastasis at initial diagnosis. Treatment options for recurrent or previously metastatic NPC are limited, with a median survival of around 20 months.

[0003] Tumor immunotherapy is a hot topic in the field, utilizing and mobilizing cytotoxic T cells in cancer patients to kill tumors. PD-1 (programmed death-1) antibodies can specifically recognize and bind to PD-1 on the surface of lymphocytes, blocking the PD-1 / PD-L1 signaling pathway, thereby activating the immune killing effect of T cells against tumors and mobilizing the body's immune system to eliminate tumor cells. Epigenetic alterations are closely related to cancer development and drug resistance. Further research has revealed drug resistance after repeated administration of PD-1 antibodies to patients. Currently, several multinational pharmaceutical companies are developing monoclonal antibodies targeting PD-1, which maximize the patient's own immune system response to tumors by blocking the binding between PD-L1 and PD-1, thereby achieving the goal of killing tumor cells. BMS, Merck, and WO2015085847 (publication date 2015.06.18) have disclosed PD-1 monoclonal antibodies, which are currently cutting-edge PD-1 antibody drugs. The FDA has approved PD-1 antibodies for monotherapy in multiple tumors, including malignant melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, liver cancer, and lymphoma. The FDA has not yet approved PD-1 antibody monotherapy for nasopharyngeal carcinoma, but Novartis' PDR-001 antibody is currently undergoing clinical trials for monotherapy of nasopharyngeal carcinoma.

[0004] Gemcitabine is a difluoronucleoside antimetabolite anticancer drug that disrupts cell replication. It is a water-soluble analog of deoxycytidine and a substitute for an inhibitory enzyme of ribonucleotide reductase, which is crucial for the generation of deoxyribonucleotides during DNA synthesis and repair. Cisplatin is a commonly used platinum complex with a broad antitumor spectrum and effectiveness against hypoxic cells. However, it is toxic to the kidneys, nervous system, and pancreas. It can bind to DNA to form cross-links, thereby disrupting DNA function and preventing replication; at high concentrations, it also inhibits RNA and protein synthesis. It is a cell cycle nonspecific drug. Another characteristic of this drug is its effect on hypoxic cells. After entering the human body, it can diffuse across charged cell membranes. It is relatively stable under high Cl- ion concentrations. After entering cells, due to the low intracellular Cl- concentration, the drug hydrolyzes into cationic hydrates, which have bifunctional groups similar to alkylating agents, mainly interacting with bases on the DNA chain.

[0005] PD-1 monoclonal antibodies combined with chemotherapy have shown promising results in non-small cell lung cancer and have received FDA approval. Studies in bladder and breast cancer are also underway. However, reports of PD-1 monoclonal antibodies combined with chemotherapy in nasopharyngeal carcinoma are rare. We hope to further improve the effectiveness of PD-1 combined with chemotherapy in the treatment of nasopharyngeal carcinoma. Summary of the Invention

[0006] The technical problem to be solved by the present invention is to provide the use of a combination of an immunotherapy agent, a nucleoside antimetabolite and a platinum complex in the preparation of a drug for treating nasopharyngeal carcinoma. This combined treatment method shows the advantages of good safety, high efficacy and low adverse reactions such as toxicity.

[0007] The technical solution of the present invention is as follows:

[0008] This invention provides the use of an immunotherapeutic agent, a nucleoside antimetabolite, and a platinum complex in the preparation of a medicament for treating nasopharyngeal carcinoma, wherein the immunotherapeutic agent is selected from PD-1 antibodies.

[0009] PD-1 antibodies are known, and preferably the light chain variable region of the PD-1 antibody includes LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0010] The heavy chain variable region of the PD-1 antibody includes HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively.

[0011] The CDR sequences mentioned above are shown in the table below:

[0012] name sequence serial number HCDR1 SYMMS SEQ ID NO: 1 HCDR2 TISGGGANTYYPDSVKG SEQ ID NO: 2 HCDR3 QLYYFDY SEQ ID NO: 3 LCDR1 LASQTIGTWLT SEQ ID NO: 4 LCDR2 TATSLAD SEQ ID NO: 5 LCDR3 QQVYSIPWT SEQ ID NO: 6

[0013] Preferably, the PD-1 antibody is a humanized antibody.

[0014] The preferred humanized antibody light chain variable region sequence is the sequence shown in SEQ ID NO: 10 or a variant thereof, wherein the variant preferably has 0-10 amino acid changes in the light chain variable region, more preferably an amino acid change of A43S; the humanized antibody heavy chain variable region sequence is the sequence shown in SEQ ID NO: 9 or a variant thereof, wherein the variant preferably has 0-10 amino acid changes in the heavy chain variable region, more preferably an amino acid change of G44R.

[0015] The variable region sequences of the heavy and light chains of the aforementioned humanized antibody are shown below:

[0016] Heavy chain variable region

[0017]

[0018] Light chain variable region

[0019]

[0020] The preferred humanized antibody light chain sequence is the sequence shown in SEQ ID NO: 8 or a variant thereof; the variant preferably has an amino acid change of 0-10 in the variable region of the light chain; more preferably, it has an amino acid change of A43S.

[0021] The humanized antibody heavy chain sequence is the sequence shown in SEQ ID NO: 7 or a variant thereof; the variant preferably has 0-10 amino acid changes in the variable region of the heavy chain; more preferably, it has G44R amino acid changes.

[0022] The humanized antibody light chain sequence is particularly preferred to be the sequence shown in SEQ ID NO: 8, and the heavy chain sequence is the sequence shown in SEQ ID NO: 7.

[0023] The sequences of the heavy and light chains of the aforementioned humanized antibody are shown below:

[0024] Heavy chain

[0025]

[0026] Light chain

[0027]

[0028] In a preferred embodiment of the present invention, the nucleoside antimetabolite is selected from gemcitabine, mercaptopurine, nelarabine, fludarabine, cladribine, clofarabine, azacitidine, ancitabine, trisatabine, capecitabine, and decitabine, with gemcitabine being preferred.

[0029] In some embodiments, the platinum complex is selected from cisplatin, carboplatin, nedaplatin, oxaliplatin, or lobaplatin, with cisplatin being preferred.

[0030] In a preferred embodiment of the present invention, the tumor is selected from malignant tumors and benign tumors; the malignant tumor is selected from malignant epithelial tumors, sarcomas, myeloma, leukemia, lymphoma, melanoma, head and neck tumors, brain tumors, mixed tumors, and childhood malignant tumors; the malignant epithelial tumor is selected from lung cancer, breast cancer, liver cancer, pancreatic cancer, colorectal cancer, gastric cancer, gastroesophageal adenocarcinoma, esophageal cancer, small bowel cancer, cardia cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, vulvar cancer, testicular cancer, prostate cancer, penile cancer, kidney cancer, bladder cancer, anal cancer, gallbladder cancer, bile duct cancer, teratoma, and cardiac tumors; the head and neck tumor is selected from nasopharyngeal carcinoma, laryngeal cancer, thyroid cancer, tongue cancer, and oral cancer; the sarcoma is selected from Askin's tumor, chondrosarcoma, and Ewing's sarcoma. The following are considered malignant tumors: hemangioendothelioma, malignant schwannoma, osteosarcoma, and soft tissue sarcoma; myeloma is selected from solitary myeloma, multiple myeloma, diffuse myeloma, leukemic myeloma, and extramedullary myeloma; leukemia is selected from acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, hairy cell leukemia, T-cell lymphoblastic leukemia, large granular lymphoblastic leukemia, and adult T-cell leukemia; lymphoma is selected from non-Hodgkin lymphoma and Hodgkin lymphoma; brain tumor is selected from neuroepithelial tumors, cranial nerve and spinal cord nerve tumors, and meningeal tumors; childhood malignant tumor is selected from nephroblastoma, neuroblastoma, retinoblastoma, and childhood germ cell tumors.

[0031] In another preferred embodiment of the present invention, the nasopharyngeal carcinoma is selected from tumors that have not previously received any chemotherapy, are recurrent, metastatic, unsuitable for local treatment, or have recurred or metastasized after radiotherapy, preferably nasopharyngeal carcinomas that have not previously received any chemotherapy, are unsuitable for local treatment, or have recurred or metastasized after radiotherapy.

[0032] In a preferred embodiment of the present invention, the tumor is resistant or drug-resistant to the immunotherapeutic agent or immunotherapy. Preferably, the immunotherapeutic agent targets PD-1 and / or PD-L1 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4); the immunotherapy is selected from immune checkpoint blockade (ICB) therapy, chimeric antigen receptor T-cell immunotherapy (CAR-T therapy), and autologous cell immunotherapy (CIK therapy).

[0033] In a preferred embodiment of the present invention, the immunotherapeutic agent is preferably selected from PD-1 antibodies, PD-L1 antibodies, and CTLA-4 antibodies. The PD-1 antibodies include, but are not limited to, Pidilizumab, MEDI-0680, AMP-224, PF-06801591, TSR-042, JS-001, GLS-010, PDR-001, Genolimzumab, Camrelizumab, BGB-A317, IBI-308, REGN-2810, Pembrolizumab, and Nivolumab. The PD-L1 antibodies include, but are not limited to, MSB-0011. 359-C, CA-170, LY-3300054, BMS-936559, Durvalumab, Avelumab, Atezolizumab; the CTLA-4 antibodies include, but are not limited to, ipilimumab, AK-104, JHL-1155, ATOR-1015, AAGEN-1884, PRS-010, tremelimumab, IBI-310, MK-1308, BMS-986218, SN-CA21, FPT-155, KN-044, CG-0161, ONC-392, AAGEN-2041, PBI-5D3H5.

[0034] In a preferred embodiment of the present invention, the use of PD-1 antibody in combination with nucleoside antimetabolites and platinum-based drugs in the preparation of drugs that enhance T-cell activity is provided, wherein the T cells are preferably peripheral T-cells.

[0035] In a preferred embodiment of the present invention, the dosage of the immunotherapy agent is selected from 1-10 mg / kg, preferably 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, and more preferably 3 mg / kg, 4 mg / kg, 5 mg / kg.

[0036] In a preferred embodiment of the present invention, the dosage of the immunotherapy agent is selected from 50-600mg, preferably 50mg, 60mg, 70mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 375mg, 400mg, 425mg, 450mg, 475mg, 500mg, 600mg, and more preferably 100mg, 200mg, 400mg.

[0037] In a preferred embodiment of the present invention, the dose of the nucleoside antimetabolite is selected from 5-1000 mg / m². 2 Preferred from 5mg / m 2 6mg / m 2 7mg / m 2 8mg / m 2 9mg / m 2 10mg / m 2 12mg / m 2 15mg / m 2 20mg / m 2 25mg / m 2 30mg / m 2 35mg / m 2 40mg / m 2 50mg / m 2 60mg / m 2 75mg / m 2 80mg / m 2 85mg / m 2 90mg / m 2 100mg / m 2 110mg / m 2 150mg / m 2 180mg / m 2 200mg / m 2 250mg / m 2 300mg / m 2 350mg / m 2 400mg / m 2 450mg / m 2 500mg / m 2 550mg / m 2 600mg / m 2 650mg / m 2 700mg / m 2 800mg / m 2 900mg / m 2 1000mg / m 2More preferably 7mg / m 2 10mg / m 2 12mg / m 2 15mg / m 2 20mg / m 2 25mg / m 2 30mg / m 2 40mg / m 2 50mg / m 2 75mg / m 2 100mg / m 2 150mg / m 2 180mg / m 2 200mg / m 2 300mg / m 2 400mg / m 2 500mg / m 2 600mg / m 2 700mg / m 2 800mg / m 2 900mg / m 2 Or 1000mg / m 2 .

[0038] In a preferred embodiment of the present invention, the dose of the nucleoside antimetabolite is selected from 5-2000 mg, preferably from 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 1000 mg, 1200 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 2000 mg, more preferably 10 mg, 20 mg, 100 mg, 200 mg, 300 mg, 500 mg, 1000 mg, or 1500 mg.

[0039] In a preferred embodiment of the present invention, the dosage of the platinum complex is selected from 5-200 mg / m². 2 Preferred from 5mg / m 2 6mg / m 2 7mg / m 2 8mg / m 2 9mg / m 2 10mg / m 2 12mg / m 2 15mg / m 2 20mg / m 2 25mg / m 230mg / m 2 35mg / m 2 40mg / m 2 50mg / m 2 60mg / m 2 75mg / m 2 80mg / m 2 85mg / m 2 90mg / m 2 95mg / m 2 100mg / m 2 120mg / m 2 125mg / m 2 130mg / m 2 150mg / m 2 160mg / m 2 180mg / m 2 180mg / m 2 190mg / m 2 195mg / m 2 200mg / m 2 More preferably 7mg / m 2 10mg / m 2 12mg / m 2 15mg / m 2 20mg / m 2 25mg / m 2 30mg / m 2 40mg / m 2 50mg / m 2 75mg / m 2 80mg / m 2 .

[0040] In a preferred embodiment of the present invention, the dosage of the platinum complex is selected from 5-400 mg, preferably from 10 mg, 15 mg, 20 mg, 25 mg, 40 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 130 mg, 135 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 180 mg, 185 mg, 190 mg, 200 mg, 250 mg, 300 mg, 400 mg, and more preferably from 10 mg, 20 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg.

[0041] In a preferred embodiment of the present invention, the combination further comprises a fourth component, which is selected from one or more of alkylating agents, platinum complexes, nucleoside anticancer agents, metabolic antagonists, plant alkaloids, hormonal anticancer agents, proteasome inhibitors, aromatase inhibitors, immunomodulators, EGFR inhibitors, ALK inhibitors, PARP inhibitors, VEGF antibodies, VEGFR inhibitors, and mTOR inhibitors. Preferably, the chemotherapeutic agent is selected from one or more of alkylating agents, platinum complexes, metabolic antagonists, plant alkaloids (such as vinca alkaloids and holoharina alkaloids), hormonal anticancer agents, proteasome inhibitors, aromatase inhibitors, and immunomodulators. In another preferred embodiment, the chemotherapeutic agent includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan, busulfan, nimustine, ramustine, dacarbazine, temozolomide, nitrogen mustard hydrochloride, dibromomannitol, cisplatin, carboplatin, oxaliplatin, nedaplatin, methotrexate, 5-fluorouracil, and tegacil. Fluoride, decitabine, capecitabine, fulvestrant, pemetrexed, anthracycline antibiotics, mitomycin, bleomycin derivatives, actinomycin, vinblastine, camptothecin derivatives, paclitaxel, vincristine, vinblastine, vindesin, etoposide, docetaxel, paclitaxel, albumin-bound paclitaxel, paclitaxel liposomes, irinotecan, vinorelbine, mitoxantrone, vinflunine, topotecan, leuprorelin, goserelin, dutasteride, fulvestrant, dexamethasone, tamoxifen, bortezomib, lenalidomide, exemestane, letrozole, anastrozole.

[0042] Preferably, the targeted drug is selected from one or more therapeutic agents chosen from EGFR inhibitors, ALK inhibitors, PARP inhibitors, VEGF antibodies and VEGFR inhibitors, and mTOR inhibitors. These targeted drugs are well known in the art; for example, EGFR inhibitors are selected from one or more of gefitinib, erlotinib, icotinib, afatinib, cetuximab, and trastuzumab; ALK inhibitors are selected from one or more of crizotinib, ceritinib, axitinib, and brigatinib; VEGF antibodies are selected from one or more of bevacizumab, brolucizumab, vanucizumab, navicixizumab, ranibizumab, and conbercept; and VEGFR inhibitors are selected from one or more of sunitinib, apatinib, and famitinib.

[0043] In some embodiments, the fourth component is selected from decitabine, carboplatin, paclitaxel albumin, paclitaxel liposomes, paclitaxel, docetaxel, cyclophosphamide, doxorubicin, and tetrahydrouridine.

[0044] In the preferred embodiments of the present invention described above, the fourth component can be selected based on the patient's body surface area, weight, or the KPS functional status score or the ECOG performance status score (Zubrod-ECOG-WHO), and the recommended dosage and administration regimen for different types of tumor chemotherapy regimens in various oncology treatment guidelines. For example, the dosage of paclitaxel albumin is 50-500 mg / m². 2 Preferred concentration: 125 mg / m 2 The dosage of decitabine is 5-500 mg / m². 2 Preferred concentration: 5-100 mg / m³ 2 ; .

[0045] In this invention, the treatment cycle can be 1 day, 3 days, 1 week, 2 weeks, or 3 weeks, preferably 3 weeks.

[0046] In this invention, the treatment cycle includes, but is not limited to, chemotherapy cycles, radiotherapy cycles, or other related targeted drug treatment cycles or immunotherapy cycles.

[0047] In this invention, immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes can be used in combination to treat tumors during the same or different treatment cycles. During the treatment of tumors, the immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes can be administered simultaneously, before, or after the combined administration, and can also be combined with chemotherapy, radiotherapy, targeted small molecule drug therapy, or immunotherapy regimens selected according to different tumors. The immunotherapy regimens include, but are not limited to, cell immunotherapy (such as CAR-T therapy, tumor vaccines, CIK therapy, etc.). In addition, the combined administration of immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes can also be performed alone without the combination of other treatment regimens.

[0048] In this invention, immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes can be used in combination to treat tumors of different pathological types and stages of progression, in accordance with various tumor diagnosis and treatment guidelines or principles. These guidelines or principles include, but are not limited to, NCCN (National Comprehensive Cancer Network, which publishes clinical practice guidelines for various malignant tumors) or the malignant tumor diagnosis and treatment guidelines issued by the Ministry of Health of China.

[0049] In this invention, within one treatment cycle, immunotherapy agents, nucleoside antimetabolites, and platinum complexes are administered concurrently or before or after nucleoside antimetabolites. Preferably, gemcitabine can be administered on days 1, 2, 3, 4, 5, 6, and 7 after the PD-1 antibody administration is completed, preferably on days 1 and 8. Cisplatin can be administered on days 1, 2, 3, 4, 5, 6, and 7 after the PD-1 antibody administration is completed, preferably on day 1. Each treatment cycle is 3 weeks, and the combination therapy can be used for a maximum of 6 cycles. Afterward, PD-1 antibody can be used alone for maintenance therapy until the end of the treatment cycle.

[0050] In this invention, the invention further provides the use of the drug, wherein the immunotherapy agent is administered once a day, twice a day, three times a day, once a week, once every two weeks, or once every three weeks; the nucleoside antimetabolite is administered once a day, twice a day, three times a day, once a week, once every two weeks, once every three weeks, once a month, or once every two months; and the platinum complex is administered once a day, twice a day, three times a day, once a week, once every two weeks, once every three weeks, or once a month.

[0051] In a preferred embodiment of the present invention, the administration is carried out in a 3-week cycle, wherein the dosage of the PD-1 antibody is 60 to 600 mg, administered intravenously on day 1 of each cycle; and the dosage of the nucleoside antimetabolite is 200 mg to 2000 mg / m². 2 Administered intravenously on days 1 and 8 of each cycle; the dosage of platinum complex is 5 to 200 mg / m². 2 Administered intravenously on day 1 of each cycle; for a maximum of 2-12 cycles, followed by maintenance therapy with PD-1 antibody alone until disease progression, intolerable toxicity, subject request, or investigator's determination that the subject is unfit to continue treatment.

[0052] In a preferred embodiment of the present invention, the administration is carried out in a 3-week cycle, wherein the dosage of the PD-1 antibody is 80 to 300 mg, administered intravenously on day 1 of each cycle; and the dosage of the nucleoside antimetabolite is 500 to 1500 mg / m². 2 Administered intravenously on days 1 and 8 of each cycle; the dosage of platinum complex is 10 to 100 mg / m². 2 Administered intravenously on day 1 of each cycle; for a maximum of 3-10 cycles, followed by maintenance therapy with PD-1 antibody alone until disease progression, intolerable toxicity, subject request, or investigator's determination that the subject is unfit to continue treatment.

[0053] In a preferred embodiment of the present invention, the administration is carried out in a 3-week cycle, wherein the dosage of the PD-1 antibody is 200 mg, administered intravenously, on day 1 of each cycle; and the dosage of the nucleoside antimetabolite is 1000 mg / m². 2 Administered intravenously on days 1 and 8 of each cycle; the dosage of platinum-based complexes is 80 mg / m². 2 Administered intravenously on day 1 of each cycle; up to 6 cycles, followed by maintenance therapy with PD-1 antibody alone until disease progression, intolerable toxicity, subject request, or investigator's judgment that the subject is unfit to continue treatment.

[0054] In a preferred embodiment of the invention, the immunotherapeutic agent is administered by injection, such as subcutaneous or intravenous injection, and must be formulated into an injectable form before injection. A particularly preferred injectable form of the immunotherapeutic agent is an injection solution or lyophilized powder for injection, comprising an immunotherapeutic agent, a buffer, a stabilizer, and optionally a surfactant. The buffer may be selected from one or more of acetate, citrate, succinate, and phosphate. The stabilizer may be selected from sugars or amino acids, preferably disaccharides, such as sucrose, lactose, trehalose, and maltose. The surfactant is selected from polyoxyethylene hydrogenated castor oil, glycerol fatty acid esters, and polyoxyethylene sorbitan fatty acid esters, preferably polysorbate 20, 40, 60, or 80, with polysorbate 20 being the most preferred. The most preferred injectable form of the immunotherapeutic agent comprises a PD-1 antibody, an acetate buffer, trehalose, and polysorbate 20.

[0055] The combined administration routes described in this invention are selected from oral administration, parenteral administration, and transdermal administration, wherein parenteral administration includes, but is not limited to, intravenous injection, subcutaneous injection, and intramuscular injection.

[0056] This invention provides a combination of the above-mentioned immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes as a therapeutic agent to prepare a drug for treating tumors and / or enhancing T-cell activity.

[0057] In this invention, a method for treating tumors and / or enhancing T-cell activity is provided, comprising administering the above-mentioned immunotherapeutic agents, nucleoside antimetabolites, and platinum complexes to a patient.

[0058] The present invention also provides a drug kit or a drug packaging box containing the aforementioned immunotherapeutic agents, nucleoside antimetabolites and platinum complexes. Detailed Implementation Invention Details

[0060] To facilitate understanding of this invention, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains.

[0061] The term "humanized antibody," also known as a CDR-grafted antibody, refers to an antibody generated by grafting a mouse CDR sequence into the variable region framework of a human antibody, i.e., a different type of human germline antibody framework sequence. This can overcome the strong antibody-variable antibody response induced by chimeric antibodies due to carrying a large number of mouse protein components. Such framework sequences can be obtained from public DNA databases or publicly available references that include germline antibody gene sequences. For example, germline DNA sequences of human heavy chain and light chain variable region genes can be found in the "VBase" human germline sequence database (available at www.mrccpe.com.ac.uk / vbase) and in Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest, 5th edition. In a preferred embodiment of the invention, the CDR sequence of the PD-1 humanized antibody is selected from SEQ ID NO: 1, 2, 3, 4, 5, 6.

[0062] The term "antigen-binding fragment" refers to Fab fragments, Fab' fragments, F(ab')2 fragments, and Fv fragments (sFv fragments) that bind to human PD-1, possessing antigen-binding activity; and includes one or more CDR regions selected from SEQ ID NO: 1 to SEQ ID NO: 6 containing the antibody described in this invention. The Fv fragment contains variable regions of the antibody heavy chain and light chain, but no constant region, and is the smallest antibody fragment with all antigen-binding sites. Generally, Fv antibodies also contain a polypeptide linker between the VH and VL domains and are capable of forming the structure required for antigen binding. Two antibody variable regions can also be linked into a single polypeptide chain using different linkers, called a single-chain antibody or single-chain Fv (sFv). The term "binding to PD-1" in this invention refers to the ability to interact with human PD-1. The term "antigen-binding site" in this invention refers to a discontinuous three-dimensional spatial site on the antigen that is recognized by the antibody or antigen-binding fragment of this invention.

[0063] The term "immunotherapy" refers to the use of the immune system to treat diseases. In this invention, it mainly refers to stimulating and enhancing the body's anti-tumor immune response by improving the immunogenicity of tumor cells and their sensitivity to killing effector cells, and by infusing immune cells and effector molecules into the host body to work synergistically with the body's immune system to kill tumors and inhibit tumor growth.

[0064] The following embodiments are used to further describe the present invention, but these embodiments are not intended to limit the scope of the present invention.

[0065] Example 1: PD-1 antibody combined with gemcitabine and cisplatin for the treatment of recurrent or metastatic nasopharyngeal carcinoma

[0066] 1. Test antibodies and compounds

[0067] The heavy and light chain sequences of the PD-1 antibody are as shown in SEQ ID NO: 7 and SEQ ID NO: 8 of this invention. 200 mg / vial, prepared as 40 mg / ml for later use.

[0068] Commercially available gemcitabine lyophilized powder for injection is available in 1.0g vials. For preparation instructions, please refer to the product information leaflet.

[0069] Commercially available cisplatin injection is available in a 20ml:20mg solution. For preparation instructions, please refer to the product information leaflet.

[0070] 2. Enrolled subjects

[0071] (1) Patients with pathologically confirmed nasopharyngeal carcinoma (primary metastatic nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma unsuitable for local treatment), who have never received systemic chemotherapy for recurrent or metastatic nasopharyngeal carcinoma, except for those who received neoadjuvant chemotherapy, concurrent chemotherapy or adjuvant chemotherapy 6 months prior to the first dose; have measurable lesions; ECOG score 0-1.

[0072] (2) Age 18-70 years old;

[0073] 3. Administration method

[0074] PD-1 antibody (200 mg / dose, on day 1 of each cycle, administered at least 30 minutes before chemotherapy, intravenous infusion >30 minutes), gemcitabine (1000 mg / m²) 2 On days 1 and 8 of each cycle, administer intravenous infusion for 30 minutes and cisplatin (80 mg / m²). 2The medication is administered intravenously over 4 hours on day 1 of each cycle. Each treatment period lasts 3 weeks. Dosing more than 3 days after the last dose in a treatment cycle is considered delayed, and subsequent doses are calculated from the actual date of the previous dose. Combination therapy is used for a maximum of 6 cycles, followed by maintenance therapy with PD-1 antibody alone until disease progression, intolerable toxicity, subject request, or investigator's judgment that the subject is unsuitable to continue treatment. As of October 27, 2017, 23 cases were enrolled, with 22 used for evaluation.

[0075] Table 1. Efficacy of the PD-1 antibody combined with gemcitabine and cisplatin in treating primary nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma unsuitable for local treatment.

[0076]

[0077] Experimental conclusion:

[0078] As shown in Table 1, the three-component combination therapy of PD-1 antibody, gemcitabine, and cisplatin achieved a response rate of 90.9% and a control rate of 100% in recurrent or metastatic nasopharyngeal carcinoma, demonstrating good safety and efficacy.

Claims

1. The use of anti-PD-1 antibody, gemcitabine, and cisplatin in the preparation of drugs for the treatment of nasopharyngeal carcinoma; among which, The light chain variable region of the anti-PD-1 antibody includes LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable region of the anti-PD-1 antibody includes HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively.

2. The use as described in claim 1, characterized in that, The anti-PD-1 antibody is a humanized antibody.

3. The use as described in claim 2, characterized in that, The light chain variable region sequence of the humanized antibody is as shown in SEQ ID NO:

10.

4. The use as described in claim 2, characterized in that, The heavy chain variable region sequence of the humanized antibody is as shown in SEQ ID NO:

9.

5. The use as described in claim 2, wherein the humanized antibody light chain sequence is the sequence shown in SEQ ID NO:8, and the heavy chain sequence is the sequence shown in SEQ ID NO:

7.

6. The use as described in claim 1, characterized in that, The nasopharyngeal carcinoma was selected from tumors that had not previously received any chemotherapy, were recurrent, metastatic, unsuitable for local treatment, or had recurred or metastasized after radiotherapy.

7. The use as described in claim 6, characterized in that, The nasopharyngeal carcinomas mentioned are selected from those who have not previously received any chemotherapy, are not suitable for local treatment, or have recurred or metastasized after radiotherapy.

8. The use as described in claim 6, characterized in that, The dosage of the anti-PD-1 antibody is selected from 1-10 mg / kg.

9. The use as described in claim 8, characterized in that, The anti-PD-1 antibody dose is selected from 1 mg / kg, 3 mg / kg, 5 mg / kg, 8 mg / kg, and 10 mg / kg.

10. The use as described in claim 8, characterized in that, The dosage of the anti-PD-1 antibody is selected from 1 mg / kg, 3 mg / kg, and 10 mg / kg.

11. The use as described in claim 8, characterized in that, The dose of the anti-PD-1 antibody is selected from 50-600 mg.

12. The use as described in claim 11, characterized in that, The anti-PD-1 antibody dose is selected from 50mg, 60mg, 70mg, 100mg, 150mg, 200mg, 300mg, 400mg, 500mg, and 600mg.

13. The use as described in claim 11, characterized in that, The anti-PD-1 antibody dose is selected from 60mg, 200mg, and 400mg.

14. The use as described in claim 6, characterized in that, the gemcitabine dose is selected from 5-2000 mg / m 2 .

15. The use as described in claim 14, characterized in that, the gemcitabine dose is selected from 5 mg / m 2 , 10 mg / m 2 , 20 mg / m 2 , 40 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 300 mg / m 2 , 500 mg / m 2 , 800 mg / m 2 , 1000 mg / m 2 , 2000 mg / m 2 .

16. The use as described in claim 14, characterized in that, the gemcitabine dose is selected from 100 mg / m 2 , 500 mg / m 2 , 800 mg / m 2 , or 1000 mg / m 2 .

17. The use as described in claim 14, characterized in that, The gemcitabine dosage is selected from 5-2000 mg.

18. The use as described in claim 17, characterized in that, The gemcitabine dosage is selected from 10mg, 100mg, 200mg, 500mg, 800mg, 1000mg, 1500mg, and 2000mg.

19. The use as described in claim 17, characterized in that, The gemcitabine dosage is selected from 100 mg, 500 mg, 1000 mg or 1500 mg.

20. The use as described in claim 6, characterized in that, The cisplatin dosage is selected from 5-200 mg / m². 2 .

21. The use as described in claim 20, characterized in that, The cisplatin dosage was selected from 5 mg / m². 2 10mg / m 2 20mg / m 2 50mg / m 2 80mg / m 2 100mg / m 2 150mg / m 2 200mg / m 2 .

22. The use as described in claim 20, characterized in that, The cisplatin dosage was selected from 10 mg / m². 2 50mg / m 2 80mg / m 2 .

23. The use as described in claim 20, characterized in that, The cisplatin dosage is selected from 5-400 mg.

24. The use as described in claim 23, characterized in that, The cisplatin dosage is selected from 10mg, 20mg, 40mg, 100mg, 160mg, 200mg, 300mg, and 400mg.

25. The use as described in claim 23, characterized in that, The cisplatin dosage is selected from 20 mg, 100 mg, and 160 mg.

Citation Information

Patent Citations

  • PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

    WO2015085847A1

  • PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

    CN105026428A